Patent Law Weblog
recent posts
- Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (2026)
- Constellation Designs, LLC v. LG Electronics Inc. (Fed. Cir. 2026)
- Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2026)
- PTAB Reverses § 101 Rejection Where Examiner Failed to Follow the Office’s Own Guidance
- Collision Communications v. Samsung: What Good Did the Government’s Statement of Interest Do?
about
Month: August 2009
-
By Donald Zuhn — A recent article in Signals Magazine reports that biotech and specialty pharma companies raised 41% more revenue in the first six months of 2009 ($8.3 billion) than they did in the same period in 2008 ($5.9 billion) ("Biotech Financing Gathers Steam"). Despite the overall rise in funding for the first…
-
By Kevin E. Noonan — One of the benefits of the exponential increase in genetic information consequent to the determination of the genomic DNA sequence of numerous species (the various "genome projects" that include the Human Genome Project) is that it permits sequence comparisons between related species. One result of this new knowledge has…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. Aventis Pharma S.A. et al. v. Sun Pharmaceutical Industries Ltd. et al.3:09-cv-04333; filed August 24, 2009 in the District Court of New…
-
By Kevin E. Noonan — The genetic age, characterized by numerous genome projects (not the least of which is the Human Genome Project) has focused the public's attention on the influence of our genes on our characteristics. This has led to questions about whether there is a "gene" for risk-taking, or homosexuality, or aggressiveness. …
-
September 1, 2009 – Prior Art & Obviousness 2009: The PTO & CAFC Perspective on Patent Law Sections 102 & 103 (Practising Law Institute) – San Francisco, CA September 2, 2009 – Biotechnology/Chemical/Pharmaceutical Customer Partnership Meeting (U.S. Patent and Trademark Office) – 10:00 am – 4:45 pm (EDT) September 13-15, 2009 – 2009 Annual Meeting…
-
The Institute for International Research (IIR) will be holding its 10th Annual Generic Drugs Summit entitled "Business of Biosimilars: Innovative Tools and Strategies to Compete in the Evolving Biosimilars Market" on September 23-25, 2009 in Boston, MA. The Business of Biosimilars conference will offer presentations on the following topics: • Update on proposed biosimilars legislation;•…
-
C5 (UK) will be holding its 17th Forum on Biotech Patenting on October 20-21, 2009 in London, United Kingdom. The conference will allow attendees to collect up-to-date information and insights on: • Recent changes in policy and patentability criteria: Hear directly from the EPO;• The latest EPO decisions impacting key aspects of biotech patenting such…
-
By Donald Zuhn — Last spring, Patent Docs discussed pending follow-on biologics legislation with California Healthcare Institute (CHI) president and CEO Dr. David Gollaher (see "CHI CEO on Patent Reform and Follow-on Biologics Legislation"). During the discussion, Dr. Gollaher mentioned that Deloitte Consulting LLP (a subsidiary of CHI member Deloitte LLP) had released its…
-
By Donald Zuhn — The Federal Circuit today vacated-in-part and affirmed-in-part an order by the District Court for the District of New Jersey granting summary judgment of invalidity of U.S. Reissued Patent No. 39,221 based on anticipation and obviousness. Plaintiff-Appellant Ortho-McNeil Pharmaceutical, Inc. owns the '221 patent, which relates to a tramadol and acetaminophen…
-
By Kevin E. Noonan — Some (bad) ideas are a long time a-dyin'. One of the most persistent in biotechnology patent law is the concept of the "tragedy of the anticommons." An intriguing idea when first proposed by Heller and Eisenberg in 1998, it was also frightfully naïve about the "anticommons" effects of circumstances…
Patent Docs 